Design and evaluation of a novel methodology for SABR for lung cancer.

• Research type

  Research Study

• Full title

  Design and evaluation of a novel methodology for stereotactic ablative radiotherapy for lung cancer: reducing treatment side-effects and enabling more patients to benefit from this treatment.

• IRAS ID

  262953

• Contact name

  V Ezhil

• Contact email

  veniezhil@nhs.net

• Sponsor organisation

  The Royal Surrey NHS Foundation Trust

• Clinicaltrials.gov Identifier

  NCT04928755

• Duration of Study in the UK

  0 years, 11 months, 30 days

• Research summary

  Aims: To increase the number of patients that benefit from Stereotactic Ablative Radiotherapy (SABR) for lung cancer using new treatment methods that reduce the amount of non-cancer tissue receiving a high radiation dose without affecting tumour dose coverage.

  Background: SABR is a treatment for lung cancer which offers major advantages over conventional radiotherapy. It is a more precise highly effective treatment with significantly improved treatment outcomes (greater elimination of cancer cells).
  SABR requires high doses per treatment so extreme accuracy is required to minimise healthy tissue damage. Normal breathing results in significant tumour movement, therefore to avoid missing the tumour, larger volumes need to be treated, resulting in more good tissue damage.

  UK Standard practice requires the tumour to be irradiated in all positions during breathing whilst the new approach targets the tumours at the position it spends most time to minimise normal tissue affected by radiation.
  Current practice for SABR patients would be improved (fewer severe radiation side-effects) and potentially could become a viable treatment for high risk patients.

  Methods: 30 SABR patients receiving current standard SABR treatment will be recruited. This is an observation study in which patients will continue to receive standard of care but in addition:

  • A camera will be used to make videos of how the patient’s chest moves in 3D at CT and treatment. I will build a complex mathematical model that infers movement of the tumour from movement of the chest.

  • Their breathing patterns, corresponding tumour motions and treatments plans will be utilised to develop a method for safely implementing the new treatment approach.

• REC name

  London - Brighton & Sussex Research Ethics Committee

• REC reference

  21/LO/0613

• Date of REC Opinion

  15 Oct 2021

• REC opinion

  Further Information Favourable Opinion